Merlin's Consolidation Wizardry
This article was originally published in Start Up
Executive Summary
If there is plenty of start-up capital in Europe, the problem is at the next financing stages, says Chris Evans, the founder and chairman of Merlin Biosciences. Not even a small fraction of the current start-ups will be able to raise their next round of funding. Merlin's hands-on venture investing will lead it to play the consolidator among Europe's start-ups.